Key result
Enoxaparin shows no benefit over UFH for reducing 48-hour MI in NSTE-ACS.
Why the study?
Evidence regarding whether enoxaparin or unfractionated heparin provides greater benefit at 48 hours and 14 days in acute coronary syndrome is limited.
Does enoxaparin reduce death, MI, or urgent revascularization compared to unfractionated heparin in patients with NSTE-ACS?
Meta-Analysis (n=17,644)
Does enoxaparin reduce death, MI, or urgent revascularization compared to unfractionated heparin in patients with NSTE-ACS?
Relative Risk: 0.87 (95% CI 0.75–1.01)
In patients with NSTE-ACS, enoxaparin showed no significant difference compared to unfractionated heparin in reducing the composite of death or MI at 48 hours and 14 days.
Supports either agent as initial therapy in NSTE-ACS; confirms equivalence on early MI in meta-analysis.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bertoli et al. (2024) conducted a meta-analysis in Acute Coronary Syndrome Without ST-Segment Elevation (NSTE-ACS) (n=17,644). Enoxaparin vs. Unfractionated Heparin (UFH) was evaluated on Myocardial infarction (MI) at 48h (RR 0.87, 95% CI 0.75-1.01). Enoxaparin presented similar results compared to unfractionated heparin, with no significant difference in myocardial infarction at 48 hours (RR 0.87) in patients with NSTE-ACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: